2024
DOI: 10.1002/dc.25270
|View full text |Cite
|
Sign up to set email alerts
|

Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda Category III in an endemic region

Zeliha Aydın Kasap,
Burçin Kurt,
Elif Özsağır
et al.

Abstract: BackgroundThis study aims to develop a diagnostic model to help physicians determine whether thyroid nodules categorized as atypia of undetermined significance (AUS) in category III of the Bethesda system are benign or malignant preoperatively. To create a diagnostic model for predicting thyroid nodules' benign or malignant with AUS cytology based on clinical, ultrasonographic, and cytopathological findings.MethodsThis is a retrospective cohort study involving patients (>19) at risk of thyroid cancer who ha… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 35 publications
0
3
0
Order By: Relevance
“…about the risk of malignancies, recurrence, and the clinical management of nodules in Bethesda category III, as the reported risks of malignancy vary significantly from 6 to 52% [18][19][20].…”
Section: Fnac Techniquementioning
confidence: 99%
See 1 more Smart Citation
“…about the risk of malignancies, recurrence, and the clinical management of nodules in Bethesda category III, as the reported risks of malignancy vary significantly from 6 to 52% [18][19][20].…”
Section: Fnac Techniquementioning
confidence: 99%
“…As a result, clinicians are better equipped to recommend appropriate clinical interventions, including close monitoring, repeat fine needle aspiration, or surgical excision, based on the individualized risk assessment of AUS/FLUS nodules [17]. Nevertheless, there are controversial data about the risk of malignancies, recurrence, and the clinical management of nodules in Bethesda category III, as the reported risks of malignancy vary significantly from 6 to 52% [18][19][20].…”
Section: Introductionmentioning
confidence: 99%
“…As a result, clinicians are better equipped to recommend appropriate clinical interventions, including close monitoring, repeat fine needle aspiration, or surgical excision, based on the individualized risk assessment of AUS/FLUS nodules [17]. Nevertheless, there are controversial data about the risk of malignancies, recurrence and clinical management of nodules in Bethesda categories III, as the reported risks of malignancy vary significantly, from 6 to 52% [18][19][20].…”
Section: Introductionmentioning
confidence: 99%